Company ProfilePremium

KH Neochem Co., Ltd.

Company Profile Analysis

Ticker: 4189.Tネオケム株式会社

ESOMAR 23 Corporate BadgeISO Certifications Badge
KH Neochem Co., Ltd. - Company showcase

Year Founded & Workforce

1966

863 Employees

KH Neochem Co., Ltd. logo

KH Neochem Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

KH Neochem Co., Ltd. Overview

KH Neochem is a mid-cap Japanese specialty chemicals company built around one core process, oxo synthesis. In this process, olefins such as propylene react with "oxo gas," a mixture of carbon monoxide and hydrogen, to produce aldehydes. The aldehydes are then converted into alcohols and carboxylic acids. On this platform the company has built three positions.

Functional Materials: It claims the world's No.1 position in raw materials for refrigeration oil (isononanoic acid and 2-ethylhexanoic acid). These feed the synthetic polyol ester lubricants used in air conditioners that run on low global-warming-potential (GWP) refrigerants.

Electronic Materials: It is a leading supplier of ultra-high-purity PGME/PGMEA solvents used in photoresists, which ties it to AI-driven semiconductor demand.

Basic Chemicals: It is Japan's leading oxo-alcohol producer. This business is under structural pressure from Chinese overcapacity.

Functional and Electronic Materials produced about 93% of FY2025 business-field operating income on about 60% of sales. The company combines a 53.6% equity ratio, high free cash flow and an increasingly shareholder-focused capital policy. In August 2026 it raised its payout target to 50% and its dividend-on-equity (DOE) floor to 5%. This came while activist Strategic Capital held about 18% of the shares.


Company's own description

The FY2025 Annual Securities Report describes the group as consisting of the company, four subsidiaries and one affiliate. Its principal business is manufacturing and selling petrochemical products, using "oxo technology" as its core technology to supply distinctive chemical products to a wide range of industries.

The company began mass-producing aldehydes by the oxo process in 1970. Since then it has extended its product range downstream into alcohols and fatty acids, which supply solvents, plasticizer raw materials and functional materials to customers in Japan and abroad. The company reports a single segment, the "Chemicals Business." It discloses sales and operating income by three business fields:

  • Functional Materials

  • Electronic Materials

  • Basic Chemicals

[ASR FY2025, Section 1.3]

The corporate mission is to "realize a better tomorrow through the power of chemistry." VISION 2030 aims for the company to become "a specialty chemical company that shines globally." [ASR FY2025]

Independent characterization

KH Neochem is a mid-stream, process-integrated chemical converter. It buys naphtha-cracker derivatives, chiefly propylene and ethylene, from neighbouring cracker operators in the Yokkaichi (Mie) and Chiba (Ichihara) industrial complexes. It also buys LNG for energy and CO2 for oxo gas. It converts these through oxo, hydrogenation, oxidation and esterification steps into roughly three tiers of product.

  1. Commodity oxo alcohols and solvents (Basic Chemicals). Examples are n-butanol, 2-ethylhexanol ("octanol"), isononyl alcohol ("Oxocol 900") and butyl acetate. These sell into plasticizers (DOP and DINP), acrylates, coatings and inks. Margins move with naphtha and Asian spreads and have compressed sharply as Chinese oxo capacity has come online. The FY2025 business-field operating margin was 2.0%.

  2. Specialty acids and diols (Functional Materials). The key products are isononanoic acid (brand "Kyowanoic-N"), octylic acid (2-ethylhexanoic acid) and cosmetic-grade 1,3-butylene glycol. These are niche, technically demanding molecules with few global producers, sold under long qualification cycles to refrigeration-oil makers and cosmetics formulators. The FY2025 margin was 19.3%.

  3. Ultra-high-purity electronic solvents (Electronic Materials). These are PM-P (PGME) and PMA-P (PGMEA) with metal content controlled at parts-per-trillion levels. In addition, subsidiary Kurokin Kasei does contract manufacturing of advanced semiconductor materials. The FY2025 margin was 21.8%.

Revenue model. The company earns essentially 100% product revenue from batch and continuous chemical sales. There is no meaningful service, subscription or licensing revenue. The one historical exception was technology-licensing income of about JPY 1.0 billion booked in 2016 from the aborted Taiwan joint venture. Revenue is recognized on delivery in Japan or on Incoterms risk transfer for exports. Certain toll-processing arrangements are recognized net, as are agent sales. [ASR FY2025, revenue recognition note]

Value-chain position. The company is downstream of crackers and refiners. Its customers include:

  • Idemitsu Kosan, its largest customer at 17.5% of FY2025 sales. Analyst inference: this is consistent with Idemitsu's position as a major refrigeration-oil formulator.

  • Miyako Chemical, a trading house and former affiliate sold to Chori in 2015, at 9.9% of sales.

  • Photoresist makers, including cross-shareholder Tokyo Ohka Kogyo.

  • Plasticizer makers, including its own J-Plus joint venture.

  • Paint companies such as Kansai Paint, and cosmetics manufacturers.

[ASR FY2025]

End markets.

  • Air conditioners and refrigeration

  • Semiconductors and flat-panel displays

  • Automotive (coatings, laminated-glass interlayers, wire coatings)

  • Housing and construction (wallpaper, flooring)

  • Cosmetics and personal care

  • Pharmaceuticals and agrochemical intermediates

Customer types. All customers are business-to-business industrial buyers. Japan accounted for 76.0% of FY2025 sales by customer location, China 11.2%, other Asia 6.8% and the rest of the world 6.0% (derived from [ASR FY2025] segment note). A large share of domestic sales are ultimately exported. For example, refrigeration-oil raw materials sold to Japanese lubricant formulators end up in Chinese and Indian air-conditioner compressors.

Sales mix by business field, FY2025 (JPY million)

Source: [ASR FY2025, MD&A]. Business-field operating income excludes company-wide administrative costs, which are shown as "Corporate costs."

Strategy

Stated strategy

VISION 2030, "A specialty chemical company that shines globally," has three aims [ASR FY2025]:

  1. Supply specialty chemical materials that help curb global warming and support better lives.

  2. Expand world-share-No.1 products and new businesses in the strategic domains of Environment, Healthcare and Electronics.

  3. Achieve top-class operating margins among domestic chemical companies.

The original VISION 2030 numbers were sales of JPY 180 billion, operating income above JPY 25 billion, an operating margin of 15%, and ROE above 12% [V2030]. The 2018 materials also set an aspiration of 75% global share in refrigeration-oil raw materials by 2030.

5th MTP (2025–2027), "Toward a New Growth Stage" [MTP5; ASR FY2025]:

Strategy I: Strengthen earning power: - Functional Materials: use the "world No.1" capacity and global logistics network for refrigeration-oil raw materials; source competitive raw materials; raise productivity; expand sales of high-quality cosmetics raw materials, including inbound-tourism demand and overseas distribution.

  • Electronic Materials: expand sales to the leading-edge semiconductor segment and add value through quality.

  • Basic Chemicals: rationalize production and logistics, work with raw-material suppliers, and apply appropriate pricing. The FY2025 report adds "accelerate structural reform."

  • Target: the functional chemicals share of cumulative EBITDA rises from 77% (4th MTP) to 82%.

Strategy II: Lay the groundwork for the future: Move new products from "exploration" to "creation" (PHB, glycans, alicyclic optical monomers). Achieve the 2030 GHG target (-30% versus FY2017) early, during the MTP.

Strategy III: Strengthen the management foundation: Build plant capability (smart safety, predictive diagnostics, advanced process control); pursue DX (an in-house generative AI environment); invest in human capital (job-based HR system, selective leadership development, mid-career hiring, an HR business-partner role in plants from 2025).

Medium-term financial targets

MetricFY2024 actualFY2025 actualFY2027 target
Operating income (JPY bn)12.211.216.5
EBITDA (JPY bn)17.217.623.6
ROE (%)131115
ROIC (%)101012
EBITDA margin (%)141518
EBITDA per employee (JPY M)212028
MetricTarget
Operating incomeJPY 44.9 billion
EBITDAJPY 65.3 billion
Functional Materials EBITDAJPY 48.9 billion
Electronic Materials EBITDAJPY 11.1 billion
Basic Chemicals EBITDAJPY 12.9 billion. This is shown as 13.6 in one version of the MTP pages, a source discrepancy.

Cumulative 2025–2027 targets:

Source: [MTP5]; [ASR FY2025] KPI table.

The FY2027 operating income target is given as JPY 16.5 billion in [ASR FY2025] and [MTP5] page 35. One third-party summary of [MTP5] cites JPY 20.5 billion; that figure is inconsistent with the EBITDA target of JPY 23.6 billion, so JPY 16.5 billion is used here.

Progress check (derived). FY2025 operating income (JPY 11.2 billion) plus FY2026 guidance (JPY 13.5 billion) totals JPY 24.7 billion. Reaching the cumulative JPY 44.9 billion would require JPY 20.2 billion in FY2027. That is about 22% above the FY2027 single-year target. The cumulative target is very likely to be missed unless FY2026 materially beats guidance.

Capital allocation (5th MTP)

UseJPY Bn
Operating cash flow source (cumulative 2025–2027)48.0
Growth and foundation investment (R&D, DX, maintenance and renewal)18.0
Strategic investment window (M&A, restructuring, additional returns)13.5
Shareholder returns16.5

Source: [MTP5].

Initiatives announced in the last 24 months (October 2024 – October 2026)

DateInitiativeDetail
Dec 2024Capital and business alliance with Beneino TechnologiesGlycan-enhanced disulfide-rich peptide (DRP) drug discovery [ASR FY2024]
7 Feb 20255th MTP launchTargets as above; payout raised to 40%; DOE at least 4%
7 Feb 2025Share buybackUp to 2.5 million shares / JPY 5.0 billion; completed by September 2025
Feb 2025Chiba CO2 recovery unit commissionedReduces CO2 procurement risk and Scope 1 emissions
2,025HR business partners placed in plants; job-based HR extended[ASR FY2025]
2,025In-house generative AI rolled out with a training program[ASR FY2025]
2,025Chiba Plant obtains new certification under the High Pressure Gas Safety ActYokkaichi was certified in 2024 [ASR FY2025]
From 2024Internal carbon price of JPY 10,000 per tonne of CO2Applied to investment decisions
2,026Basic Chemicals structural reform accelerated[ASR FY2025]. Specific measures such as capacity closures or partnerships had not been disclosed as of October 2026.
Aug 2026Planned construction of a new Yokkaichi power-generation facility (JPY 350 million)August 2026 to April 2028
4 Aug 2026Dividend policy upgradePayout about 50% (from 40%); DOE at least 5% (from 4%); applies from FY2026 [DIV 0804]
11 May 2026Additional Board Benefit Trust contributionExecutive equity incentive

Products & Services

Pricing models for the products below are not publicly disclosed. The company states that it passes raw-material and fuel cost changes into selling prices "in a timely and appropriate manner" [ASR FY2025]. Analyst inference: this is consistent with naphtha-linked formula pricing for Basic Chemicals and negotiated contract pricing for specialties.

Functional Materials

Product / brandChemistryKey specifications and capabilitiesTarget customer and applicationLaunch / latest capacityFlagship status
Kyowanoic-NIsononanoic acid (3,5,5-trimethylhexanoic acid)Branched C9 acid. It is esterified with polyols to make polyol ester (POE) refrigeration oils that are compatible with HFC and low-GWP refrigerants such as R32 and R454B.Refrigeration-oil formulators (Idemitsu Kosan is the largest disclosed customer) supplying air-conditioner compressor makers worldwideYokkaichi expansion in 2020 (about 1.5x); Chiba expansion completed July 2024 (about 1.5x, JPY 9.5 billion project)Core flagship. The company claims world No.1 share in refrigeration-oil raw materials. [MTP5]; [ASR FY2025]
Octylic acid2-Ethylhexanoic acid (2-EHA)Used as a co-acid in POE refrigeration oils. Also used to make the plasticizer (3G8) for PVB laminated-glass interlayers in automotive and architectural glass, and in metal soaps.Refrigeration-oil makers; PVB film makers; coatingsLong-established; capacity included in the 2020 and 2024 expansionsFlagship
1,3-Butylene glycol (1,3-BG)Specialty diolHumectant with high moisturizing power, low skin irritation and mild antibacterial action. The company has developed low-odor, high-purity grades by analyzing and suppressing trace impurities.Cosmetics and skincare makers in Japan and Asia, including premium skincareOngoing quality upgrades; sales expansion through overseas distributionThe company claims No.3 globally in cosmetics raw materials. [Integrated Report 2025]
Diacetone acrylamide (DAAM)Acrylamide monomerCrosslinking monomer for water-based paintsPaint and coatings makers—Niche
Other specialty diols, acids and intermediatesVariousUsed in lubricants, adhesives, pharmaceutical and agrochemical intermediates, and surfactantsIndustrial and pharmaceutical customers—Niche

Electronic Materials

Product / brandChemistryKey specifications and capabilitiesTarget customer and applicationLaunch / latest capacityFlagship status
PMA-PHigh-purity propylene glycol monomethyl ether acetate (PGMEA)Ultra-low metal impurities (parts-per-trillion class). Quality is held consistent lot to lot using statistical process control. Primary photoresist casting solvent.Photoresist makers and semiconductor fabs (logic, memory and advanced AI nodes); display makersQuality-control building with an industry-leading cleanroom opened at Yokkaichi in 2022Flagship. The company claims world No.1 in high-purity solvents. [Integrated Report 2025]
PM-PHigh-purity propylene glycol monomethyl ether (PGME)Same quality regime as PMA-P. Used as a co-solvent and in thinner/edge-bead removal formulations.Same customers as PMA-PSame as PMA-PFlagship
Kurokin Kasei advanced semiconductor materialsContract-manufactured high-function organic materialsSpecifics are confidential to customers. Research and production-engineering teams move products from lab to commercial production.Semiconductor materials makers; electronics and medical customersFirst unit autumn 2020; large unit autumn 2024Growth engine
EUV-related solvent developmentPGMEA / PGME derivativesJoint university research is validating the solvent's role in EUV lithography.Leading-edge fabsIn developmentPipeline

Basic Chemicals

Product / brandChemistryApplicationsNotes
Octanol2-Ethylhexanol (2-EH)Raw material for DOP plasticizer (wallpaper, flooring, automotive parts) and 2-ethylhexyl acrylate (paints, adhesives, pressure-sensitive adhesives, resins)Core oxo alcohol
Oxocol 900Isononyl alcohol (INA)Raw material for DINP plasticizer (wall and floor materials, automotive parts, wire coatings)Feeds the J-Plus joint venture with Mitsubishi Chemical
Butanoln-ButanolCoatings solvent (automotive, building exteriors, cans); resin raw materialCommodity
Butyl acetaten-Butyl acetateCoatings and ink solventCommodity
Butyraldehyde and other aldehydesOxo intermediatesMainly captive usePlatform intermediates

The company claims domestic No.1 share in oxo alcohols. [Integrated Report 2025]

Other

BusinessDescription
Kurokin Fines Co., Ltd.Trading company (a subsidiary of Kurokin Kasei) selling health-food raw materials, pharmaceutical raw materials and industrial chemicals [ASR FY2025]

Pipeline / new businesses (5th MTP "Strategy II: Laying the Groundwork for the Future")

ProgramDescriptionStated milestone
Marine-biodegradable resin (PHB, polyhydroxybutyrate)Produced by fermentation ("bio-manufacturing") from renewable feedstockBuild a mass-production system during the 5th MTP (by 2027) [MTP5]
Glycans for biopharmaceuticalsA library of more than 100 glycan types, with kg-scale mass-production technology established. Partner: GlyTech, Inc. (糖鎖工学研究所).Commercialize during the 5th MTP period [ASR FY2025]
Next-generation optical lens materials (alicyclic compounds / monomers)Oxo-derived monomers that offer heat resistance, low dielectric properties and low water absorption, for automotive (ADAS), smartphone and 5G/6G camera lensesPilot production and paid samples underway; commercial plant "as early as 2027" [MTP5]
BiostimulantsCo-development with Accplanta Inc. to improve crop tolerance of climate stressField trials [ASR FY2025]
CO2 utilizationCO2 captured at Chiba (unit commissioned February 2025) and Yokkaichi is reused as oxo-gas feedstockOperating [ASR FY2025]

Financial Narrative

Income statement

Sources: [ASR FY2025] five-year summary, P&L and dividend data; Envalith/EDINET DB for gross profit, SG&A and EBITDA.

EBITDA here follows the company's definition: operating income plus depreciation plus goodwill amortization. Diluted EPS equals basic EPS because no potentially dilutive shares exist. [ASR FY2025]

Margins (%, derived)

Revenue CAGR, FY2021–FY2025: -0.4% per year (derived). Measured from the COVID-depressed FY2020 base of about JPY 77.3 billion, the five-year average growth was 8.3% [MKT]. The three-year average growth rate is 0.1%.

Balance sheet

Source: [ASR FY2025]; [TAN FY24]. FY2021–FY2022 shareholders' equity is derived as equity ratio multiplied by total assets.

Debt and working-capital detail (FY2023–FY2025, JPY million)

Source: [ASR FY2025]; [ASR FY2024].

Company material from 2018–2022 indicates net debt was on a declining trend through 2021.

Cash flow: notes and sources

Source: [ASR FY2025]. FCF is derived.

Source: [ASR FY2025]; [ASR FY2024].

Ratios (derived unless stated)

Sources: [ASR FY2025]; Envalith for ROA.

ROIC is per the company's KPI table [ASR FY2025]. EDINET DB computes a pre-tax ROIC of 13.4% for FY2025, a methodological difference.

Commentary on trends, inflections and drivers

FY2021 was a cyclical peak, not the base. Operating income nearly tripled to JPY 19.7 billion. The company attributes the gain to two factors:

  • JPY 8.9 billion from wider price spreads, as Asian oxo markets were tight because of competitor outages and naphtha was rising (which created inventory gains).

  • JPY 7.2 billion from volume and mix [MTP4 / FY2021 results deck].

ROE of 27.9% reflected this exceptional environment. FY2022 to FY2023 saw spread normalization. Gross margin fell 8.5 percentage points over two years, and operating income bottomed at JPY 9.9 billion in FY2023.

FY2024 was the specialty-led recovery. Operating income rose 22.6% to JPY 12.2 billion. Functional Materials operating income rose 31% on air-conditioner demand, particularly in India and other emerging markets, plus cost pass-through. Electronic Materials operating income rose 28% on AI-related demand. Cash conversion, however, was weak. OCF of JPY 7.0 billion was hit by a JPY 4.6 billion increase in receivables. Capex of JPY 8.4 billion (cash basis) for the Chiba expansion produced negative FCF.

FY2025 was a disappointment against plan. The original guidance of sales JPY 127.4 billion and operating income JPY 14.0 billion was missed by a wide margin. Actual sales were JPY 115.1 billion and operating income JPY 11.2 billion, 20% below guidance. Through the first nine months, operating income had been up 16% year on year. The shortfall therefore came almost entirely in Q4 2025: derived Q4 operating income was about JPY 2.7 billion. The company cited three causes:

  • An air-conditioner inventory correction in the second half, from US pre-buying ahead of the refrigerant change and fading Chinese subsidies.

  • Unseasonable weather in emerging markets.

  • A one-off raw-material procurement problem in Basic Chemicals [ASR FY2025, Issues to Address].

Higher depreciation from the Chiba plant (JPY 6.2 billion versus JPY 4.8 billion) also weighed. Cash generation was strong, though. OCF doubled to JPY 13.8 billion on receivable collection, funding JPY 8.6 billion of shareholder returns.

Balance sheet. The equity ratio rose from 45.0% to 53.6% over four years even as the company returned capital. Net debt of about JPY 10 billion is about 0.6 times EBITDA. The working-capital cycle lengthened in FY2025 to 111 days as inventory rose JPY 3.6 billion ahead of planned turnarounds and during the air-conditioner correction. This is a monitorable for FY2026.

FY2026 year to date: inflection. First-half operating income was JPY 7.5 billion, up 25% year on year, with a margin of 14.1%. This was the best first half since FY2021. The quarterly progression matters:

  • Q1 FY2026 operating income was JPY 2.1 billion, down 22.6%.

  • Q2 standalone operating income was about JPY 5.4 billion (derived). That is up about 64% year on year and is the strongest quarter since 2021.

Electronic Materials, up 51%, and a Basic Chemicals price-led recovery drove the result. Functional Materials remains in correction.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Business Field Details

Business fieldWhat it containsKey productsProduction sites

Functional Materials

Refrigeration-oil raw materials; cosmetics raw materials; other specialty acids and diols

Kyowanoic-N (isononanoic acid), octylic acid (2-EHA), 1,3-butylene glycol; diacetone acrylamide

Yokkaichi, Chiba

Electronic Materials

High-purity solvents for photoresists and displays; advanced semiconductor materials made by contract at Kurokin Kasei

PM-P (PGME), PMA-P (PGMEA); Kurokin Kasei next-generation semiconductor materials

Yokkaichi (including the 2022 quality-control building); Kurokin Kasei (Chiryu and Minokamo)

Basic Chemicals

Solvents, plasticizer raw materials, resin raw materials

n-Butanol, octanol (2-ethylhexanol), Oxocol 900 (isononyl alcohol), butyl acetate

Yokkaichi, Chiba

Other

Trading and miscellaneous, mainly Kurokin Fines (health-food and pharma ingredients)

——

Revenue by Segment

Business fieldFY2023FY2024FY2025

Functional Materials sales (JPY Mn)

50,37455,87456,686

Electronic Materials sales (JPY Mn)

11,66811,96112,309

Basic Chemicals sales (JPY Mn)

52,35251,18945,374

Other sales (JPY Mn)

822733727

Total net sales (JPY Mn)

115,217119,758115,098

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Segment — Functional Materials OI

Business fieldFY2023FY2024FY2025

Functional Materials OI (JPY Mn)

8,43011,06310,931

Electronic Materials OI (JPY Mn)

1,8832,4072,681

Basic Chemicals OI (JPY Mn)

2,6111,970916

Other OI (JPY Mn)

16762129

Corporate costs (JPY Mn)

-3,146-3,308-3,410

Consolidated operating income (JPY Mn)

9,94612,19511,248

Segment Margins & Growth (%)

MetricFY2023FY2024FY2025

Functional Materials OI margin (%)

16.719.819.3

Electronic Materials OI margin (%)

16.120.121.8

Basic Chemicals OI margin (%)

5.03.82.0

Functional Materials sales YoY (%)

—10.91.5

Electronic Materials sales YoY (%)

—2.52.9

Basic Chemicals sales YoY (%)

—-2.2-11.4

Functional Materials % of total sales

43.746.749.3

Electronic Materials % of total sales

10.110.010.7

Basic Chemicals % of total sales

45.442.739.4

Segment Revenue

Business fieldQ1 FY2026 salesQ1 YoY (%)Q1 FY2026 OIQ1 OI YoY (%)1H FY2026 sales1H YoY (%)1H FY2026 OI1H OI YoY (%)

Functional Materials

12,109-17.62,156-16.124,850-15.1—-10.4

Electronic Materials

3,365+22.5754+33.07,360+26.31,817+51.3

Basic Chemicals

9,942-11.0191-58.2—-10.92,296+270.5

Consolidated

25,581-11.22,094-22.653,299-9.37,501+24.9

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Net sales (JPY Mn)

117,110114,880115,217119,758115,098

Cost of sales (JPY Mn)

84,87690,43493,27994,50490,232

Gross profit (JPY Mn)

32,23324,44521,93725,25324,866

SG&A (JPY Mn)

12,54711,98911,99113,05713,618

Operating income (JPY Mn)

19,68512,4569,94612,19511,248

EBITDA, company definition (JPY Mn)

24,18816,74914,59717,16817,581

Ordinary income (JPY Mn)

19,80912,7099,72512,05510,793

Pre-tax income (JPY Mn)

19,78811,6349,72511,91810,793

Income taxes (JPY Mn)

5,9243,3822,7953,4472,839

Net income attributable to owners (JPY Mn)

13,6918,0736,8268,3607,799

EPS basic (JPY)

368.95217.73184.23225.81218.15

EPS diluted (JPY)

368.95217.73184.23225.81218.15

Dividends per share (JPY)

75859090105

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin (%)

27.521.319.021.121.6

Operating margin (%)

16.810.88.610.29.8

EBITDA margin (%)

20.714.612.714.315.3

Net margin (%)

11.77.05.97.06.8

Effective tax rate (%)

29.929.128.728.926.3

Balance Sheet and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (JPY Mn)

122,069131,247124,498131,462130,101

Cash and equivalents (JPY Mn)

16,93410,9269,6847,1586,719

Net assets (JPY Mn)

57,50562,06666,49371,91972,629

Shareholders' equity (JPY Mn)

54,91959,35063,74469,08869,676

Equity ratio (%)

44.9945.2251.2052.5553.56

Book value per share (JPY)

1,480.271,601.261,720.811,866.631,990.25

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Balance Sheet

MetricFY2023FY2024FY2025

Interest-bearing debt excluding leases (JPY Mn)

14,82017,74716,949

of which short-term borrowings (JPY Mn)

—9,7509,950

of which commercial paper (JPY Mn)

02,9961,999

of which bonds, long-term (JPY Mn)

—5,0005,000

Lease obligations (JPY Mn)

—1,4581,341

Net interest-bearing debt excluding leases (JPY Mn)

5,13510,58810,230

Goodwill (JPY Mn)

—840705

Other intangibles (JPY Mn)

—506448

Current assets (JPY Mn)

—69,36667,253

Current liabilities (JPY Mn)

—46,64945,231

Working capital (JPY Mn)

—22,71722,022

Inventories (JPY Mn)

—20,71224,270

Trade receivables (JPY Mn)

—37,33732,877

Trade payables (JPY Mn)

—24,40822,398

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (JPY Mn)

17,4025,13113,2016,98213,783

Investing cash flow (JPY Mn)

-4,395-10,082-4,937-8,897-4,627

Financing cash flow (JPY Mn)

-5,168-1,076-9,501-645-9,566

FCF proxy, OCF plus investing CF (JPY Mn)

13,007-4,9518,264-1,9159,156

Dividends & Capital Returns

MetricFY2024FY2025

Purchase of PP&E, cash basis (JPY Mn)

8,4324,653

Capital expenditure, accrual basis (JPY Mn)

6,6034,231

Depreciation (JPY Mn)

4,8396,199

Goodwill amortization (JPY Mn)

134134

Dividends paid (JPY Mn)

3,3423,540

Share repurchases, including Board Benefit Trust (JPY Mn)

695,054

Total shareholder returns (JPY Mn)

3,4118,594

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2021FY2022FY2023FY2024FY2025

ROE, company-reported (%)

27.8614.1311.0912.5911.24

ROA, net income / average assets (%)

11.26.25.56.46.0

Asset turnover (x)

—0.910.900.940.88

Dividend payout, parent-only, company-reported (%)

21.1040.8748.0341.4149.02

Returns & Leverage Ratios (%) and Financial Ratios (x) (FY2023–FY2025)

MetricFY2023FY2024FY2025

ROIC, company KPI basis (%)

—1010

Current ratio (x)

—1.491.49

Debt / equity (x)

0.230.260.24

Net debt / EBITDA (x)

0.350.620.58

Interest coverage, OI / interest expense (x)

—12157

Days sales outstanding (days)

—114104

Days inventory outstanding (days)

—8098

Days payables outstanding (days)

—9491

Cash conversion cycle (days)

—100111

Revenue by Region

RegionFY2024FY2025

Japan (JPY Mn)

90,54187,503

China (JPY Mn)

15,53112,937

Other Asia (JPY Mn)

8,1397,800

Other regions (JPY Mn)

5,5456,856

Total (JPY Mn)

119,758115,098

Geographic Revenue

RegionFY2025 YoY growth (%)FY2024 share (%)FY2025 share (%)

Japan

-3.475.676.0

China

-16.713.011.2

Other Asia

-4.26.86.8

Other regions

+23.64.66.0

Per-Share Data and Capital Markets Data (JPY)

MetricFY2021FY2022FY2023FY2024FY2025

Year-end share price, derived from PER times EPS (JPY)

3,1802,6932,2702,0372,476

Annual high (JPY)

3,5403,2802,8032,4763,050

Annual low (JPY)

2,3222,3352,1401,7691,945

Total shareholder return, five-year cumulative index (%)

119.2104.592.287.0107.0

TOPIX including dividends, comparison index (%)

112.7110.0141.1169.9213.2

Change by Period

PeriodChange

Year to date (versus about JPY 2,476 at end-2025)

about +36%

Approximately 1 year (versus the 52-week low of JPY 2,315 on 21 November 2025)

+45% from the low

Approximately 3 years (versus about JPY 2,270 at end-2023)

about +48%

Approximately 5 years (versus about JPY 3,180 at end-2021)

about +6%

Valuation Multiples

MultipleKH NeochemBasis

P/E on company forecast

13.5x

Company EPS forecast of JPY 248.5 [MKT]

P/E on consensus

about 11.8x

Consensus FY2026 EPS of JPY 285.6 [MKT] (derived)

P/B

1.58x

Actual book value [MKT]

EV/EBITDA

about 7.8x

EV of about JPY 138 billion (market cap 124.8 + net debt 10.2 + non-controlling interests 3.0) divided by FY2025 EBITDA of 17.6 (derived)

EV/Sales

about 1.2x

Derived

Dividend yield

3.87%

FY2026 DPS of JPY 130

Market capitalization

JPY 124.8 billion

[MKT]

Valuation Snapshot

MetricValue

FY2026 consensus ordinary income

JPY 14.2 billion, versus company guidance of JPY 12.6 billion

FY2026 consensus EPS

JPY 285.6

FY2027 consensus EPS

JPY 317.0

12-month-forward consensus EPS

JPY 309.1

Per-Share Data and Returns & Leverage Ratios (%)

MetricFY2021FY2022FY2023FY2024FY2025

Annual DPS (JPY)

75859090105

Interim DPS (JPY)

3042.5454552.5

Consolidated payout (%)

20.339.048.939.948.1

Capital Instruments

InstrumentWithin 1 year1–2 years2–3 years3–4 years4–5 yearsOver 5 years

Short-term borrowings

9,950—————

Commercial paper

1,999—————

Bonds (issued 2024)

———5,000——

Lease obligations

118108105108110788

Analyst Conclusions

Management guidance (FY2026, unchanged since 6 February 2026)

MetricFY2025 actualFY2026 guidanceYoY (%)1H FY2026 actual1H share of full year (%)
Net sales (JPY M)115,098114,000-1.053,29946.8
Operating income (JPY M)11,24813,500+20.07,50155.6
Ordinary income (JPY M)10,79312,600+16.77,44859.1
Net income (JPY M)7,7998,700+11.55,28260.7
EPS (JPY)218.15248.45—150.85—
DPS (JPY)105130+23.855—

Source: [TAN FY25]; [TAN 1H26]; [DIV 0804].

Management's stated assumptions for FY2026 are domestic naphtha at JPY 60,000 per kilolitre and an exchange rate of USD 1 = JPY 150. The implied second-half operating income is JPY 6.0 billion, below the first half's JPY 7.5 billion. Management kept guidance because of Middle East uncertainty. This sets up a conservative bar: consensus ordinary income of JPY 14.2 billion is 13% above guidance.

Bull case

  1. Electronic Materials compounding. Operating income grew 51% in first-half FY2026. If full-year FY2026 operating income reaches about JPY 3.5–3.8 billion and the 2024 Kurokin capacity fills alongside EUV growth (46 to 205 thousand gallons over 2024–2029), this field alone could add JPY 1–2 billion of operating income by FY2027.

  2. Functional Materials normalization. The air-conditioner correction is cyclical, not structural (140 to 190 million units by 2030). With new Chiba capacity and higher depreciation already absorbed, a volume recovery from 2027 could push this field's operating income back above its FY2024 peak of JPY 11.1 billion.

  3. Capital-return re-rating plus an activist floor. A 50% payout and DOE of at least 5% imply DPS of about JPY 100 even in a downturn (5% DOE on about JPY 2,000 book value per share). With Strategic Capital at 18%, further measures are plausible: cross-shareholding sales (JPY 7.2 billion), buybacks from the JPY 13.5 billion strategic window, or Basic Chemicals restructuring. At about 7.8x EV/EBITDA and a P/B of 1.58x, a move toward the consensus target of JPY 3,850 or higher is credible.

Bear case

  1. Functional Materials is ex-growth for longer. First-half FY2026 sales fell 15%. US refrigerant transitions, the Chinese property market and air-conditioner saturation in China could keep volumes flat through 2027. Customer concentration (Idemitsu at 17.5%) limits pricing power.

  2. First-half Basic Chemicals profit is not repeatable. Operating income of JPY 2.3 billion (up 270%) appears to be driven by price increases outrunning average-cost inventory during a raw-material spike. A reversal in the second half or in FY2027, plus continued Chinese imports, could take Basic Chemicals back to about JPY 1 billion or below.

  3. Execution and credibility. The FY2025 guidance was missed by 20%. The MTP cumulative operating income target of JPY 44.9 billion requires about JPY 20 billion in FY2027, which is implausible. VISION 2030's JPY 25 billion operating income target looks out of reach, and R&D at about 1% of sales may be too thin to deliver new businesses (PHB, glycans, optical monomers) at a meaningful scale.

Catalysts and monitorables (next 12 months)

Expected timingCatalyst
Early November 2026Q3 FY2026 results. Watch for a guidance revision (consensus is above guidance) and whether Functional Materials volumes have bottomed.
From November 2026 onwardStrategic Capital's next moves. Watch for shareholder proposals ahead of the March 2027 AGM (Japanese submission deadlines are typically about 8 weeks before the AGM).
Early February 2027FY2026 results and FY2027 guidance. Watch for possible MTP target revisions, new buyback authorizations and the year-end DPS of JPY 75.
OngoingBasic Chemicals structural reform. Any capacity closure, partnership or Japanese oxo consolidation announcement.
OngoingRaw-material and FX path. Naphtha relative to the JPY 60,000 per kilolitre assumption, the Middle East situation, and JPY/USD relative to 150.
OngoingWorking capital. Whether inventory (JPY 24.3 billion at end-FY2025) normalizes after turnarounds.
2,027New-business milestones. PHB mass-production decision; alicyclic monomer facility investment decision.
March 2027 AGMVote outcomes and any further board changes

Analyst verdict

KH Neochem is a high-quality niche franchise attached to a structurally challenged commodity business, and its equity story has shifted from growth to capital efficiency.

The franchise is genuine. The company dominates refrigeration-oil raw materials and is a premium supplier of photoresist-grade solvents. Over FY2023 to FY2025 these two fields earned business-field margins of about 16–22% and generated over 90% of segment profit.

The company has nonetheless failed to grow. FY2025 sales of JPY 115.1 billion sit below FY2021's level. Operating income of JPY 11.2 billion is 43% below the FY2021 peak. Management missed its own FY2025 operating income guidance by 20%. The cumulative 5th MTP target now looks out of reach without an exceptional FY2027.

Two developments in 2026 change the debate. First, results inflected: second-quarter operating income of about JPY 5.4 billion was the strongest quarter since 2021, driven by AI-linked Electronic Materials and agile pricing. Second, the ownership register changed: Strategic Capital accumulated an 18.24% stake within four months. The board's response so far has been shareholder-friendly. A former Mizuho Securities M&A banker was added as a director, and the dividend policy was raised to a 50% payout with a DOE floor of at least 5%. The FY2026 dividend of JPY 130 is 24% higher year on year.

At about 13.5x company-guided EPS, about 7.8x EV/EBITDA, a 3.9% yield and a strong balance sheet (net debt about 0.6x EBITDA), the stock is reasonably priced for a business whose specialty core should resume growth in 2027. The real swing factors are Basic Chemicals and the activist dynamic. A credible Basic Chemicals restructuring, a buyback funded from the JPY 13.5 billion strategic window, and reduction of the JPY 7.2 billion cross-shareholding book would each lift ROE toward the 15% target without heroic operating assumptions.

Downside risks are concentrated in a prolonged air-conditioner correction and a reversal of first-half Basic Chemicals inventory gains. Net, the risk-reward is moderately favorable. The investment case rests on visible capital-return support, conservative FY2026 guidance and governance-driven optionality rather than on top-line growth, which management has yet to deliver.

The key near-term proof points are Q3 FY2026 results in early November 2026 and any activist proposals ahead of the March 2027 AGM.


Market-share rankings are company self-reported. Items labeled "analyst inference" are interpretive and not stated in company filings.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleBorn (age in Oct 2026)TenureBackground and prior roles

Michio Takahashi (髙橋理夫)

Representative Director, President & CEO, Chair of the Board

Feb 1965 (61)

Director since 2013; President since March 2019

Joined Kyowa Hakko Kogyo in 1987. Basic Chemicals division head (2011). Managing Director (2016); Executive Vice President (2017). Holds 39,619 shares including 30,619 Board Benefit Trust points.

Toshiaki Toma (藤間敏明)

Director, Senior Managing Executive Officer, Corporate Planning; Chief Strategy Officer (CSO) and Chair of the Sustainability Committee

Jul 1974 (52)

Director since March 2025

Joined Kyowa Hakko Kogyo in 1998. Postings in the US with Kyowa Hakko USA and Chemical Americas (EVP). Corporate Planning head from 2023.

Taro Hasuo (蓮尾太郎)

Director, Managing Executive Officer (appears to have succeeded to the CFO/IR contact role)

Jan 1969 (57)

Director since March 2026; joined January 2026

Joined Industrial Bank of Japan (now Mizuho) in 1992. Head of M&A Advisory at Mizuho Securities USA (2015). Executive Officer and Head of the Resources & Materials Industry Group, Mizuho Securities Global Investment Banking (2023–2025).

Sayoko Miyairi (宮入小夜子)

Outside Director (independent); Nomination & Compensation Committee member

Nov 1956 (69)

Since 2019

Partner at Scholar Consulting. Professor Emerita at Kaichi International University. Outside director at Toyo Engineering and Nippon Seikan.

Atsushi Tsuchiya (土屋淳)

Outside Director (independent); Nomination & Compensation Committee member

Oct 1952 (73)

Since 2020

Researcher at Argonne and Lawrence Berkeley national laboratories. Worked at Mitsubishi Kasei, where he was President of Verbatim. Director at Rohm and Haas Japan. President of Heraeus Japan (2007–2018).

Yuji Kikuchi (菊池祐司)

Outside Director (independent); Chair of the Nomination & Compensation Committee

Feb 1964 (62)

Since 2020

Attorney and partner at Tokyo Hatchobori Law Office. Former official at the Securities and Exchange Surveillance Commission. Outside director at Tachibana Securities (2026).

Isao Takahashi (高橋功)

Director, full-time Audit & Supervisory Committee member and committee chair

Aug 1964 (62)

Since March 2024

Formerly at Fujisawa / Astellas. Joined the company in 2017. Managing Executive Officer and head of Corporate Administration.

Keiko Tamura (田村恵子)

Outside Director (independent), Audit & Supervisory Committee member

Aug 1963 (63)

Statutory auditor from 2020; director from 2024

Partner at Asahi Law Offices. Outside director at Amano Corp. Outside auditor at Norinchukin Trust.

Yoji Murohashi (室橋陽二)

Outside Director (independent), Audit & Supervisory Committee member

Feb 1965 (61)

Since March 2026

CPA. Former Senior Partner at EY ShinNihon (until 2023).

Directors' Remuneration

CategoryTotal payFixed cashPerformance-linked cashPerformance-linked stock (Board Benefit Trust)Number of persons

Executive directors (excluding Audit Committee and outside directors)

1427631344

Internal Audit & Supervisory Committee director

2121001

Outside directors

5454005

Board & Management Changes

DateChangeContext

Mar 2024

Directors Toshihiro Matsuoka and Yukihiro Isogai retire. Isao Takahashi becomes a full-time Audit Committee director.

Conversion to the Audit & Supervisory Committee structure

Mar 2025

Director Tatsuo Shintani retires; Toshiaki Toma joins the board.

Generational renewal; Toma is the strategy lead

Jan 2026

Taro Hasuo joins from Mizuho Securities.

Analyst inference: this brings in M&A and capital-markets expertise as activist ownership builds.

26 Mar 2026

CFO Shinya Hamamoto (a former Industrial Bank of Japan banker, director since 2020) leaves the board. Outside director Kazuhiro Kawai leaves the board. Hasuo and Murohashi are elected. Toma is promoted to Senior Managing Executive Officer.

AGM

Major Shareholders

RankHolderShares%
1

The Master Trust Bank of Japan (trust account)

5,206,30014.81
2

Custody Bank of Japan (trust account)

2,827,4008.04
3

Tosoh Corporation

1,852,0005.27
4

State Street Bank & Trust 505001

1,193,2793.39
5

Mizuho Bank

733,3002.09
6

Government of Norway

655,9291.87
7

Juniper (Riyadh)

655,2001.86
8

BNY 133652

645,8001.84
9

State Street Bank & Trust 505019

521,4611.48
10

Northern Trust (Wales Pension Partnership)

517,4001.47

Major Shareholders by Holder

Holder%

Intertrust Trustees (Cayman) as trustee of JAPAN-UP. Analyst inference: this is consistent with the fund vehicle advised by Strategic Capital.

18.14

The Master Trust Bank of Japan (trust account)

12.60

Custody Bank of Japan (trust account)

8.02

Tosoh Corporation

5.27

Major Shareholders by Filer

FilerReported stake (%)Obligation dateNotes

Strategic Capital Inc. (activist; Representative Director Tsuyoshi Maruki)

18.24

17 Jun 2026

Holding rose from 13.13% (9 Mar 2026) to 14.35% (10 Mar), 15.36% (31 Mar), 16.08% (12 May), 17.08% (1 Jun), 17.59% (9 Jun) and 18.24% (17 Jun), equal to 6,774,700 shares.

Amova Asset Management (formerly Nikko AM), within the Sumitomo Mitsui Trust group

7.68

29 Dec 2025

Group total about 10.2% including Sumitomo Mitsui Trust Bank (0.49%) and SuMi Trust AM (2.01%). The bank's stake decreased in March 2026.

Trivista Capital

6.07

31 May 2023

Current holding not confirmed

Wellington Management group

3.98 + 2.98 + 0.59

15 Aug 2025

Decrease reported in March 2026

Nomura Asset Management / Nomura International

3.72 + 0.23

15 Sep 2025

—

Mizuho Bank / Mizuho Trust / Asset Management One

1.97 + 0.40 + 1.94

14 Nov 2025

—

Competitive Landscape

Competitor Detail

Field / productCompetitorCountryRelative positioning

Refrigeration-oil raw materials (isononanoic acid, 2-EHA)

OQ Chemicals (formerly Oxea)

Germany / Oman

Major global producer of isononanoic acid and 2-EHA.

Same

BASF

Germany

Large oxo and 2-EHA producer; broad portfolio

Same

Eastman Chemical

USA

2-EHA and oxo derivatives

Same

Perstorp (Petronas Chemicals)

Sweden / Malaysia

2-EHA and polyols (POE co-raw materials)

High-purity PGME / PGMEA

Dow

USA

Global glycol-ether leader

Same

Daicel

Japan

Domestic electronic-solvent competitor

Same

Shiny Chemical Industrial; Chang Chun Group

Taiwan

Large Asian PGMEA suppliers close to TSMC

Cosmetic 1,3-BG

Daicel

Japan

Major 1,3-BG producer; key domestic rival

Same

OQ Chemicals

Germany / Oman

Global 1,3-BG producer

Oxo alcohols (2-EH, butanol, INA)

Mitsubishi Chemical Group

Japan

Domestic oxo peer and joint-venture partner

Same

Chinese producers (e.g., Wanhua, Sinopec affiliates, Shandong producers)

China

Large new capacity driving imports into Japan [MTP5]

Same

LG Chem; Hanwha Solutions

Korea

Regional oxo producers

Peer Comparison FY2025

MetricKH Neochem (FY Dec-2025)Daicel (FY Mar-2026)Mitsubishi Chemical Group (latest FY)Asahi Kasei (latest FY)

Revenue (JPY Bn)

115.1579.63,7003,070

Revenue growth (%)

-3.9-1.2——

Operating margin (%)

9.87.30.87.5

ROE (%)

11.2—0.78.0

Equity ratio (%)

53.642.630.050.5

R&D / sales (%)

1.2———

Dividend yield (%)

3.9——2.8

“—” = not publicly disclosed.

Company Snapshot

$768.9M

Revenue

863

Employees

1966

Founded

SWOT Analysis

Strengths

  • A specialty earnings core. Functional and Electronic Materials produced JPY 13.6 billion of the JPY 14.7 billion in FY2025 business-field operating income (93%), at margins of 19.3% and 21.8% [ASR FY2025].
  • Global capacity leadership in refrigeration-oil raw materials after the Chiba expansion completed in July 2024 (about 1.5 times capacity; JPY 9.5 billion project) [ASR FY2024].
  • AI-semiconductor leverage. Electronic Materials operating income grew 28% (FY2024), 11% (FY2025) and 51% (first-half FY2026) [ASR; TAN 1H26].
  • Balance sheet. Equity ratio of 53.6%; net debt of JPY 10.2 billion (0.58 times EBITDA); undrawn credit lines of JPY 12.3 billion [ASR FY2025].
  • Cash generation. FY2025 OCF of JPY 13.8 billion, FCF conversion of 122% of net income (EDINET DB), and a Sloan accrual ratio of -4.6%.
  • Above-median returns. Five-year average operating margin of 11.3% and ROE of 11.2% in FY2025, against Japanese chemical medians of 7.0% and 6.5% [MKT; EDINET DB].
  • Shareholder-return commitment. Payout of about 50%, DOE of at least 5%, FY2026 DPS of JPY 130 (up 24%), and a JPY 5.0 billion buyback executed in 2025 [DIV 0804; ASR FY2025].

Weaknesses

  • No top-line growth. Sales of JPY 115.1 billion in FY2025 are below the JPY 117.1 billion of FY2021; the four-year CAGR is -0.4%.
  • Forecast credibility. FY2025 operating income came in 20% below initial guidance (JPY 11.2 billion versus JPY 14.0 billion) after nine-month operating income had been up 16%.
  • Customer concentration. Idemitsu (17.5%) and Miyako Chemical (9.9%) together account for 27.4% of sales [ASR FY2025].
  • Low R&D intensity. JPY 1.34 billion, or 1.2% of sales, in FY2025.
  • Commodity exposure. Basic Chemicals is 39% of sales at a 2.0% margin; its operating income fell 53.5% in FY2025.
  • Working-capital drag. The cash conversion cycle rose from 100 to 111 days and inventory rose JPY 3.6 billion in FY2025 (derived).
  • Long-run TSR underperformance. The five-year total shareholder return to December 2025 was 107.0%, against 213.2% for TOPIX including dividends [ASR FY2025].

Opportunities

  • Air-conditioner growth: 140 million to 190 million units by 2030, with India and other Asia gaining share [MTP5].
  • EUV photoresist volume rising about 4.5 times between 2024 and 2029 [MTP5]. The 2024 Kurokin Kasei facility can capture leading-edge materials demand.
  • New businesses: PHB mass production by 2027, a glycan library of more than 100 types at kg scale, and an alicyclic optical-monomer plant as early as 2027 [MTP5].
  • Domestic consolidation in Basic Chemicals. Japanese cracker rationalization could enable partnerships or a capacity exit, supported by the JPY 13.5 billion strategic window [MTP5].
  • Carbon advantage. CO2 is used as a feedstock, Scope 1+2 GHG emissions are already 28.8% below FY2017, and the company expects surplus GX-ETS allowances [ASR FY2025].
  • Activist catalyst. Strategic Capital holds 18.24% and could push for further capital efficiency or strategic alternatives (speculative).

Threats

  • US refrigerant-transition aftershock and Chinese demand fade. Functional Materials sales fell 15.1% in first-half FY2026.
  • Chinese oxo overcapacity is depressing Asian prices and pushing imports into Japan [MTP5; ASR FY2025].
  • Raw-material volatility from Middle East tensions. The company explicitly excluded the impact from its FY2026 forecast [TAN Q1 26].
  • Feedstock security as Japanese crackers rationalize; the company identifies a supply-disruption risk for specific raw materials [ASR FY2025].
  • Carbon pricing. At USD 130 per tonne in 2030, the potential cost is about JPY 7.1–7.3 billion per year (the annual report gives two figures) [ASR FY2025].
  • Cyber risk, which materialized at a subsidiary in 2025 [ASR FY2025].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
8 May 2025Q1 FY2025 results: sales JPY 28.8 billion (+6.8%), operating income JPY 2.7 billion (+8.5%), EBITDA JPY 4.1 billion (+13%). Full-year guidance maintained (sales JPY 127.4 billion, operating income JPY 14.0 billion, DPS JPY 105).Solid start to the 5th MTP
28 May 2025Board Benefit Trust contribution of JPY 55 million (22,300 shares)Executive equity alignment
Jul 2025Buyback continues: 186,200 shares for JPY 500.7 million in July; 1.7 million shares / JPY 4.2 billion cumulativeCapital return
4 Aug 20251H FY2025: sales JPY 58.8 billion (+5.1%), operating income JPY 6.0 billion (+24.7%), net income JPY 3.9 billion (+18.9%). Interim DPS JPY 52.50.Peak momentum before the second-half correction
15 Aug 2025Wellington Management group files about 7.5% combinedLong-only foreign interest
15 Sep 2025Nomura group large-holding report (about 4%)n/a
30 Sep 2025Buyback completed: 1,993,000 shares for JPY 4,999.8 million (5.37% of shares)Shares outstanding reduced
5 Nov 20259M FY2025: sales JPY 86.6 billion (-0.2%), operating income JPY 8.5 billion (+16.2%). Full-year guidance maintained.Guidance later proved too high
14 Nov 2025Mizuho group large-holding reportn/a
21 Nov 202552-week share-price low of JPY 2,315Sentiment trough
29 Dec 2025Amova AM / SuMi Trust group report (7.68% Amova)n/a
2025 (undated)Cyberattack on a subsidiary. Response included damage assessment and data recovery with external specialists; group-wide preventive measures are underway.Cyber risk materialized [ASR FY2025]
2025 (undated)One-off raw-material procurement problem in Basic ChemicalsContributed to the FY2025 miss
Jan 2026Taro Hasuo (formerly Mizuho Securities) joinsCapital-markets and M&A expertise
6 Feb 2026FY2025 results: sales JPY 115.1 billion (-3.9%), operating income JPY 11.2 billion (-7.8%), net income JPY 7.8 billion (-6.7%). Operating income 20% below original guidance. FY2026 guidance: sales JPY 114.0 billion, operating income JPY 13.5 billion (+20%), net income JPY 8.7 billion. DPS forecast JPY 110.Credibility hit; reset
9–10 Mar 2026Strategic Capital stake reaches 13.13%, then 14.35%Activist accumulation
25 Mar 2026FY2025 Annual Securities Report filedn/a
26 Mar 2026AGM: board renewal (Hasuo and Murohashi in; Hamamoto and Kawai out). Year-end DPS of JPY 52.50 approved.Governance change
31 Mar 2026Strategic Capital at 15.36%n/a
11 May 2026Q1 FY2026: sales JPY 25.6 billion (-11.2%), operating income JPY 2.1 billion (-22.6%). Electronic Materials operating income +33%. Guidance unchanged. Middle East impact excluded from the forecast. Additional Board Benefit Trust contribution.Weak quarter in line with plan
12 May 2026Strategic Capital at 16.08% (report also cites a change in a material contract, such as collateral)n/a
1–17 Jun 2026Strategic Capital rises to 17.08%, then 17.59%, then 18.24% (6.77 million shares)Effectively the largest shareholder
30 Jul 2026Corporate Governance Report updatedn/a
4 Aug 20261H FY2026: operating income JPY 7.5 billion (+24.9%) versus the May forecast of JPY 4.9 billion (+53%); net income JPY 5.3 billion (+34%). Price increases and agile responses to raw-material spikes offset volume losses from Middle East tensions and turnarounds. Full-year guidance unchanged.Strong beat
4 Aug 2026Dividend policy upgraded to a payout of about 50% and DOE of at least 5%. Year-end DPS raised to JPY 75; full-year FY2026 DPS raised to JPY 130 (from JPY 110).Analyst inference: a shareholder-return response in an activist context
10 Aug 202652-week share-price high of JPY 3,570Re-rating
7 Sep 2026Interim dividend of JPY 55 paidn/a
Sep 2026Monitor
1 Oct 2026Japan's GX-ETS emissions-trading compliance regime starts in FY2026. Yokkaichi and Chiba are covered; the company expects surplus allowances.Regulatory

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Net sales fell from JPY 117.1 Bn in FY2021 to JPY 115.1 Bn in FY2025.
KH Neochem Co., Ltd. — Income Statement: Revenue & Gross Profit
Series (JPY Bn)FY2021FY2022FY2023FY2024FY2025
Net sales117.1114.9115.2119.8115.1
Cost of sales84.990.493.394.590.2
Gross profit32.224.421.925.324.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.